Get the Stockscreener App
12.02
0.17%
-0.02
After Hours:
12.02
Bicara Therapeutics Inc stock is traded at $12.02, with a volume of 321.20K.
It is down -0.17% in the last 24 hours and up +2.30% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$12.04
Open:
$11.99
24h Volume:
321.20K
Relative Volume:
0.45
Market Cap:
$655.85M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.67%
1M Performance:
+2.30%
6M Performance:
-2.75%
1Y Performance:
+0.00%
1-Day Range:
$11.96
$12.25
1-Week Range:
$10.64
$12.25
52-Week Range:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
12.02 | 656.94M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Published on: 2025-08-27 14:30:15 - Newser
What momentum shifts mean for Bicara Therapeutics Inc.Weekly Earnings Recap & Weekly Breakout Opportunity Watchlist - Newser
Is now a turning point for Bicara Therapeutics Inc.2025 Key Lessons & Smart Money Movement Tracker - Newser
Chart based exit strategy for Bicara Therapeutics Inc.Market Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
Ranking Bicara Therapeutics Inc. among high performing stocks via toolsPortfolio Update Summary & Capital Efficiency Focused Strategies - Newser
How to track smart money flows in Bicara Therapeutics Inc.Quarterly Trade Review & AI Driven Stock Movement Reports - Newser
AI Indicators Detect Buy Opportunity in Bicara Therapeutics Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
What to expect from Bicara Therapeutics Inc. in the next 30 daysTrend Reversal & Weekly High Conviction Ideas - Newser
Bicara Therapeutics Inc. stock volume spike explainedBond Market & Capital Protection Trading Alerts - Newser
Visualizing Bicara Therapeutics Inc. stock with heatmapsWeekly Gains Report & Accurate Intraday Trade Tips - Newser
Top chart patterns to watch in Bicara Therapeutics Inc.Trade Performance Summary & Verified Momentum Stock Alerts - Newser
How to use Fibonacci retracement on Bicara Therapeutics Inc.Fed Meeting & Growth Focused Stock Pick Reports - Newser
Bicara Therapeutics Inc. stock trend forecastPrice Action & Stepwise Entry/Exit Trade Alerts - Newser
Bicara Therapeutics Inc. Shows Risk Reward Favoring UpsideOil Prices & Short-Term Trading Alerts - beatles.ru
Automated trading signals detected on Bicara Therapeutics Inc.Quarterly Earnings Report & Risk Managed Investment Entry Signals - Newser
Detecting price anomalies in Bicara Therapeutics Inc. with AIJuly 2025 Market Mood & Stepwise Swing Trade Plans - Newser
Bicara Therapeutics Inc. stock momentum explained2025 Technical Overview & Smart Investment Allocation Insights - Newser
Advanced analytics toolkit walkthrough for Bicara Therapeutics Inc.Trade Risk Assessment & Low Risk High Win Rate Picks - Newser
How to recover losses in Bicara Therapeutics Inc. stock2025 Momentum Check & Smart Money Movement Tracker - Newser
Will Bicara Therapeutics Inc. price bounce be sustainable2025 Big Picture & Low Risk Entry Point Tips - Newser
Bicara Therapeutics Inc. stock trend outlook and recovery path2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
Bicara Therapeutics Inc. stock prediction for this weekWeekly Trade Report & Safe Capital Growth Plans - Newser
Can Bicara Therapeutics Inc. sustain earnings growthJuly 2025 Highlights & Community Driven Trade Alerts - theviewers.co.kr
Buybacks Report: Is Bicara Therapeutics Inc. impacted by rising rates2025 Major Catalysts & Capital Efficiency Focused Ideas - theviewers.co.kr
H.C. Wainwright lowers Bicara Therapeutics stock price target to $40 on expenses By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Bicara Therapeutics stock price target to $40 on expenses - Investing.com Nigeria
Bicara Therapeutics: HC Wainwright maintains Buy, PT lowered to $40 from $41. - AInvest
Bicara Therapeutics Inc. Stock Lags Behind Sector Benchmarks2025 Volume Leaders & Safe Entry Trade Signal Reports - newsyoung.net
Bicara Therapeutics Inc. Trading Near Value Zone — Recovery AheadRecession Risk & Verified Technical Signals - 더경남뉴스
Can swing trading help recover from Bicara Therapeutics Inc. lossesWeekly Profit Report & Daily Chart Pattern Signals - Newser
Piper Sandler initiates coverage of oncology companies - MSN
Relay Therapeutics shares fall 2.45% intraday as Piper Sandler initiates coverage on Bicara Therapeutics. - AInvest
Piper Sandler initiates coverage of oncology companies (CGON:NASDAQ) - Seeking Alpha
Piper Sandler Initiates Bicara Therapeutics at Overweight - MarketScreener
Piper Sandler initiates Bicara Therapeutics stock with Overweight rating - Investing.com
Is Bicara Therapeutics Inc. stock poised for growth2025 Technical Overview & Real-Time Stock Movement Alerts - Newser
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):